Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GO 203 2c

Next Previous
Search
Drug Profile

GO 203 2c

Alternative Names: GO2032c

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genus Oncology
  • Developer Dana-Farber Cancer Institute; Genus Oncology
  • Class Antineoplastics; Peptides
  • Mechanism of Action Mucin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Discontinued Solid tumours

Most Recent Events

  • 25 Feb 2021 GO 203 2c is still in phase I/II trials for Acute myeloid leukaemia (Combination therapy, Monotherapy, Second-line therapy or greater) in USA (IV) (NCT02204085)
  • 06 Mar 2018 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV) (Genus Oncology website, March 2018)
  • 09 Dec 2017 Adverse events and efficacy data from a phase I/II trial in Acute Myeloid leukaemia presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-2017)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top